Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

Sanwa Kagaku Kenkyusho

Status and phase: Completed; Phase 3

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: miglitol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00213122

MG1007

Details and patient eligibility

About

In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.

Sex: All

Ages: 20 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• type2 diabetes
• postprandial plasma glucose levels ≧180mg/dl

Exclusion criteria

• type1 diabetes
• AST(GOT) or ALT(GPT) ≧100IU/l
• creatinine ≧2.0mg/dl

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: Single Blind